These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease. Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705 [TBL] [Abstract][Full Text] [Related]
5. Dermatologic manifestations in inflammatory bowel disease in Tunisia. Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379 [TBL] [Abstract][Full Text] [Related]
7. Treatment of erythema nodosum, aphthous stomatitis, and pyoderma gangrenosum in patients with IBD. Tremaine WJ Inflamm Bowel Dis; 1998 Feb; 4(1):68-9; discussion 73. PubMed ID: 9552230 [No Abstract] [Full Text] [Related]
8. Mucocutaneous manifestations of inflammatory bowel disease. Amatore F; Colombel JF; Delaporte E Ann Dermatol Venereol; 2024 Sep; 151(3):103301. PubMed ID: 39094469 [TBL] [Abstract][Full Text] [Related]
9. Treatment of extraintestinal manifestations of inflammatory bowel disease. Grand RJ Inflamm Bowel Dis; 1998 Feb; 4(1):72; discussion 73. PubMed ID: 9552233 [No Abstract] [Full Text] [Related]
10. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916 [TBL] [Abstract][Full Text] [Related]
11. [Cutaneous symptoms of ulcero-haemorragic rectocolitis and of Crohn's disease (author's transl)]. Thivolet J; Ortonne JP; Jeune R Ann Dermatol Venereol; 1978; 105(8-9):723-7. PubMed ID: 367248 [TBL] [Abstract][Full Text] [Related]
12. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M; PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031 [TBL] [Abstract][Full Text] [Related]
13. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Hanauer SB Inflamm Bowel Dis; 1998 Feb; 4(1):70; discussion 73. PubMed ID: 9552231 [No Abstract] [Full Text] [Related]
15. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series. Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735 [TBL] [Abstract][Full Text] [Related]
16. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Greenstein AJ; Janowitz HD; Sachar DB Medicine (Baltimore); 1976 Sep; 55(5):401-12. PubMed ID: 957999 [TBL] [Abstract][Full Text] [Related]
17. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease]. Kujundzić M Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303 [TBL] [Abstract][Full Text] [Related]